晶泰控股(02228)尾盘涨超5%，截至发稿，涨4.55%，报11.03港元，成交额14.87亿港元。 消息面上，近日，富时罗素指数公司更新9月份富时全球股票指数系列的半年度调整名单。其中，晶泰 控股获纳入富时中国小盘股。相关调整已于9月19日收盘后正式生效。分析指出，纳入国际性指数意味 着更广泛的资本关注和流动性溢价。 招商证券指出，晶泰科技AI制药业务商业化稳步推进，2025年上半年药物发现业务同比增速高达 615%，并与辉瑞、强生等多家全球顶尖药企保持长期合作，公司与DoveTree完成总订单规模59.9亿美 元的管线合作签约，并已收到协议约定的首付款5100万美元，对业绩带来增量贡献。通过共享量子物理 计算、多模态AI及自动化平台，晶泰实现了技术平台的跨领域复用，成功拓展至新能源、农业及工业 材料等多个领域。 ...

Group 1 - The core point of the article highlights that Crystal Tech Holdings (02228) saw a significant stock price increase, rising over 5% and reaching HKD 11.03, with a trading volume of HKD 1.487 billion [1] - Crystal Tech Holdings has been included in the FTSE China Small Cap Index as part of the FTSE Russell Index Company's semi-annual adjustments, effective after the market close on September 19 [1] - Inclusion in an international index indicates broader capital attention and liquidity premium for the company [1] Group 2 - According to招商证券, Crystal Tech's AI pharmaceutical business is steadily advancing towards commercialization, with a projected year-on-year growth rate of 615% in drug discovery by the first half of 2025 [1] - The company has established long-term collaborations with leading global pharmaceutical companies such as Pfizer and Johnson & Johnson [1] - Crystal Tech has signed a pipeline cooperation agreement with DoveTree, with a total order scale of USD 5.99 billion, and has received an initial payment of USD 51 million, contributing positively to its performance [1] Group 3 - The company has successfully expanded its technology platform across various fields, including new energy, agriculture, and industrial materials, by leveraging quantum physical computing, multimodal AI, and automation platforms [1]